SLC27A1 and melanoma: Lipofermata may also be exploited to inhibit FATP1 because of the similarity between FATP1 and FATP2, which contributes to the effective inhibition of FATP1-mediated fatty acid uptake, thereby reducing melanoma cell proliferation (208).